Sutro Biopharma
STRO
122 hedge funds and large institutions have $118M invested in Sutro Biopharma in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 30 closing their positions.
263% more call options, than puts
Call options by funds: $243K | Put options by funds: $67K
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
0.12% more ownership
Funds ownership: 7.63% → 7.75% (+0.12%)
6% less funds holding
Funds holding: 130 → 122 (-8)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
46% less capital invested
Capital invested by funds: $216M → $118M (-$98.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$7.85M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$4.81M |
| 3 |
Morgan Stanley
New York
|
+$3.8M |
| 4 |
BlackRock
New York
|
+$1.76M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.96M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.49M |
| 3 |
EP
Eversept Partners
New York
|
-$3.5M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.85M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.55M |
STRO Hedge Fund Activity: Q4 2024 in Review
122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2024, worth a combined $118M — down 46% from $216M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of STRO and 23 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 41 added.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $7.85M. The largest seller was Millennium Management, cutting an estimated $4.96M.
- 122 institutional investors held Sutro Biopharma (STRO) as of Q4 2024, down from 130 in Q3 2024.
- Funds reported $118M of Sutro Biopharma stock for Q4 2024, down 46% quarter-over-quarter.
- 23 funds opened new Sutro Biopharma positions in Q4 2024 and 30 closed out, a net change of -7 holders.
- The largest Sutro Biopharma buyer in Q4 2024 was Vestal Point Capital, an estimated $7.85M added.
- The largest Sutro Biopharma seller in Q4 2024 was Millennium Management, an estimated $4.96M sold.
Based on aggregated 13F filings for Q4 2024.